Nicox S.A. (NICXF)

Overview

Nicox S.A. is an ophthalmic company with a global presence, focusing on the development of innovative solutions aimed at preserving vision and enhancing ocular health. With its headquarters in Valbonne, France, and operations spanning across various countries, Nicox is at the forefront of ophthalmological research. Since its inception in 1996, the company has dedicated itself to addressing some of the most pressing challenges in eye care, particularly targeting conditions such as open-angle glaucoma, ocular hypertension, and dry eye disease. Nicox's research and development efforts are centered around leveraging nitric oxide-donating compounds to create novel treatments that offer significant improvements over existing therapies.

Products and Services

• NCX 470

A groundbreaking nitric oxide-donating bimatoprost eye drop currently in Phase 3 clinical trials. This product is designed to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension, showcasing Nicox's commitment to tackling some of the leading causes of vision loss worldwide.

• NCX 4251

This innovative treatment is a patented ophthalmic suspension of fluticasone propionate nanocrystals. Currently in Phase 2b clinical trials, NCX 4251 targets the treatment of dry eye disease, a condition affecting millions globally. By leveraging nanotechnology, Nicox aims to offer a more efficient and effective solution for this widespread issue.

• NCX 1728

Another testament to Nicox's innovative approach, NCX 1728 is a preclinical evaluation product. It is a NO-donating Phosphodiesterase-5 inhibitor, which represents a new frontier in the treatment of ocular diseases. This product underscores the company's ongoing research into novel therapeutic pathways.

• VYZULTA (latanoprostene bunod ophthalmic solution)

Already available to patients, VYZULTA is a treatment for those suffering from open-angle glaucoma or ocular hypertension. As a latanoprostene bunod ophthalmic solution, it exemplifies Nicox's ability to bring innovative products through the regulatory process and into the market, providing critical solutions for eye care professionals and their patients.

• ZERVIATE (cetirizine ophthalmic solution)

ZERVIATE is Nicox's answer to ocular itching associated with allergic conjunctivitis. As a cetirizine ophthalmic solution, it provides a novel approach to managing a prevalent eye condition, adding to the company's diverse portfolio of eye care solutions and reinforcing its position as a leader in ophthalmological innovation.